SCHEMBL6828537

SCHEMBL6828537

CCOC(=O)c1[nH]c(C)c(-c2ccc(C(=O)Nc3ccc(C(C)C)cc3)cc2)c1C

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.58
MAPK1 P28482 1/20 0.58
HTT P42858 1/20 0.58
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
SMN1; SMN2 Q16637 4/20 0.48
TSHR P16473 2/20 0.48
USP2 O75604 1/20 0.48
RAB9A P51151 5/20 0.48
NPC1 O15118 3/20 0.48
GAA P10253 1/20 0.48
LMNA P02545 3/20 0.47
KDM4E B2RXH2 2/20 0.47
TRPV1 Q8NER1 1/20 0.46
EGFR P00533 1/20 0.44
ERBB2 P04626 1/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 1/20 0.44
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6828515 0.88 MAPT (0.52) MAPTMAPK1HTTMEN1KMT2A
SCHEMBL6828198 0.87 MAPT (0.60) MAPTMAPK1HTTMEN1KMT2A
SCHEMBL6825618 0.87 MAPT (0.60) MAPTMAPK1HTTMEN1KMT2A
SCHEMBL6828203 0.87 MAPT (0.60) MAPTMAPK1HTTMEN1KMT2A
SCHEMBL6828196 0.87 LMNA (0.53) MAPTMAPK1HTTMEN1KMT2A
SCHEMBL6828188 0.86 MAPT (0.55) MAPTMAPK1HTTMEN1KMT2A
SCHEMBL6825586 0.85 MAPT (0.58) MAPTMAPK1HTTMEN1KMT2A
SCHEMBL6825312 0.84 MAPT (0.57) MAPTMAPK1HTTMEN1KMT2A
SCHEMBL6825461 0.81 MAPK1 (0.56) MAPTMAPK1HTTMEN1KMT2A
SCHEMBL26915257 0.81 RAB9A (0.72) MAPTMAPK1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040138269-A1 Substituted pyrroles as kinase inhibitors SUGEN, INC. 2004-07-15 US claimed
US-20040138269-A1 Substituted pyrroles as kinase inhibitors SUGEN, INC. 2004-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138269-A1 Substituted pyrroles as kinase inhibitors PHKG1, PHKG2, MAP3K20 MAPT 1856/4885MAPK1 277/4885HTT 1942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.